Qube Research & Technologies (QRT)’s Arcturus Therapeutics ARCT Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-25,090	Closed	-$582K	–	3436
2024 Q3	$582K	Buy	25,090 +18,488	+280%	+$396K	﹤0.01%	2214
2024 Q2	$161K	Sell	6,602 -6,640	-50%	-$201K	﹤0.01%	2489
2024 Q1	$447K	Sell	13,242 -51,718	-80%	-$1.83M	﹤0.01%	2593
2023 Q4	$2.05M	Sell	64,960 -90,496	-58%	-$2.15M	﹤0.01%	1509
2023 Q3	$3.97M	Buy	155,456 +72,143	+87%	+$2.22M	0.01%	1048
2023 Q2	$2.39M	Buy	+83,313	New	+$2.27M	0.01%	977
2023 Q1	–	Sell	-11,814	Closed	-$200K	–	2518
2022 Q4	$200K	Buy	+11,814	New	+$206K	﹤0.01%	1826
2021 Q3	–	Sell	-11,620	Closed	-$393K	–	2174
2021 Q2	$393K	Sell	11,620 -486	-4%	-$16.5K	﹤0.01%	1406
2021 Q1	$500K	Buy	+12,106	New	+$722K	0.01%	1176
2020 Q2	–	Sell	-28,057	Closed	-$381K	–	1697
2020 Q1	$381K	Sell	28,057 -39,645	-59%	-$507K	0.02%	664
2019 Q4	$736K	Buy	+67,702	New	+$709K	0.02%	764

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ARCT Position: Q4 2024 in Review

Qube Research & Technologies (QRT) sold out of Arcturus Therapeutics (ARCT) in Q4 2024, closing a stake of 25,090 shares — an estimated $582K sold.

Qube Research & Technologies (QRT) first reported a position in ARCT in Q4 2019 and held it in 11 quarters. The position peaked at $3.97M in Q3 2023. 147 funds tracked by Wall St. Rank hold ARCT as of Q4 2024.

Qube Research & Technologies (QRT) reported no remaining Arcturus Therapeutics position as of Q4 2024 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 25,090 Arcturus Therapeutics shares in Q4 2024, an estimated $582K.
Qube Research & Technologies (QRT) first reported a position in Arcturus Therapeutics in Q4 2019 and held it in 11 quarters.
Qube Research & Technologies (QRT)'s Arcturus Therapeutics position peaked at $3.97M in Q3 2023.
147 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q4 2024, filed 14 Feb 2025.